AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Pharma company announces publication of study examining Talabostat.
2004 SEP 1 - (NewsRx.com & NewsRx.net) -- Point Therapeutics, Inc., (NASDAQ: POTP) announced that a study investigating its lead product candidate talabostat (PT-100) has been published in the August edition of Cancer Research.
The study is entitled "PT-100, a Small Molecule Dipeptidyl Peptidase Inhibitor, has Potent AntiTumor Effects and Augments Antibody-mediated Cytotoxicity via a Novel Immune Mechanism."
The preclinical study showed that talabostat slowed growth or caused regression and rejection of certain experimental tumors in mice in vivo. The authors demonstrated that the antitumor effect of talabostat appears to involve tumor-specific cytotoxic T lymphocytes (CTL) and protective immunological memory. Increased mRNA expression of cytokines and chemokines known to promote T cell and other innate effector cells activity was also observed.
In addition, study data showed talabostat's ability to augment the antitumor activity of rituximab and trastuzumab in human tumor xenograft models. Antibody-dependent toxicity in these models can be mediated by innate effector cells responsive to the cytokines and chemokines upregulated by talabostat.
"Talabostat was found to have potent antitumor effects in vivo both as a single agent and in combination with tumor-specific antibodies," stated coauthor Dr. Barry Jones, Point Therapeutics senior vice president of research.
"It is an ...
- Analysis of Point Therapeutics Inc.
- Press release article from: M2 Presswire May 24, 2007 700+ words
...24 May 2007-Biotech News: Analysis of Point Therapeutics Inc(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:24052007 Analysis of Point Therapeutics Inc (NASDAQ:POTP) Point Therapeutics, Inc., a development stage biopharmaceutical...
- Point Therapeutics Raises $2.8 Million in Initial Financing
- Press release article from: PR Newswire October 14, 1997 700+ words
...BOSTON, Oct. 14 /PRNewswire/ -- Point Therapeutics, Inc. (formerly Immune Therapeutics...and Graystone Venture Partners. Point Therapeutics, a privately held company, was...a variety of therapeutic areas. Point Therapeutics has exclusively licensed this technology...
- Trade Alert for Point Therapeutics Inc.
- Press release article from: M2 Presswire May 22, 2007 700+ words
...May 2007-Biotech News: Trade Alert for Point Therapeutics Inc(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:22052007 Trade Alert for Point Therapeutics Inc (NASDAQ:POTP) Point Therapeutics, Inc., a development stage biopharmaceutical...
- Point Therapeutics Down 68% On Talabostat Clinical Hold.
- Magazine article from: BIOWORLD Today Morrison, Trista May 22, 2007 700+ words
...Morrison, Staff Writer Shares of Point Therapeutics Inc. fell 68 percent to a 52-week...to befall talabostat. In March, Point Therapeutics saw its shares drop 30 percent after...changes in the standard of care, so Point Therapeutics did not originally commit to an early...
- POTP SHARES GAIN 496 PERCENT DARA, POINT THERAPEUTICS JOIN IN REVERSE-MERGER...
- Magazine article from: BIOWORLD Today Morrison, Trista October 11, 2007 700+ words
...merger with troubled Point Therapeutics Inc., but Dara President...said his company sees Point Therapeutics as more than just a public...Hills, Mass.-based Point Therapeutics. Dara's shareholders...
- Fundamental Review for Point Therapeutics Inc.
- Press release article from: M2 Presswire November 27, 2006 700+ words
...Biotech News: Fundamental Review for Point Therapeutics Inc(C)1994-2006 M2 COMMUNICATIONS...27112006 Fundamental Review for Point Therapeutics Inc (NASDAQ:POTP) Point Therapeutics is making sure that your blood actually...
- Daily Market Alert for Point Therapeutics Inc.
- Press release article from: M2 Presswire March 1, 2007 700+ words
...Daily Market Alert for Point Therapeutics Inc.(C)1994-2007 M2...COMMUNICATIONS LTD RDATE:01032007 Point Therapeutics is making sure that your...up to date information on Point Therapeutics Inc. are invited to sign...
- Point Therapeutics Reports First Quarter 2003 Financial Results.
- Press release article from: Business Wire May 8, 2003 700+ words
...BUSINESS WIRE)--May 8, 2003 Point Therapeutics, Inc. (OTC BB: POTP.OB) today...approximately $14,300,000. ABOUT POINT THERAPEUTICS, INC.: Point is a Boston-based...name was changed at that time to Point Therapeutics, Inc., and the trading symbol...
